Hikal - Pharma & Agrochem

Stock Opportunities
42

In CY16 and CY17, Hikal filed 8 out of 25 total active DMFs currently.

Capture
Capture578×620 84.1 KB

Enjoys dominant position in Gabapentin API business. Around 30-35% market share. This API has been a significant contributor of Hikal’s pharma revenues as of FY17.

Source: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/DrugMasterFilesDMFs/UCM370722.xls

10 Likes